BARDA Scales Up COVID-19 Vaccine Manufacturing Capacity With $628m For Emergent BioSolutions
An inflection point arrives as US public sector pharma manufacturing hits 'warp speed' in COVID-19 crisis.
You may also be interested in...
After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.
US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.
Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.